Ertiprotafib, also known as PTP-112, is a Protein Tyrosine Phosphatase 1B Inhibitor (PTP1B inhibitor). Ertiprotafib normalized the plasma glucose and insulin levels in diabetic animal models, and progressed to a phase II clinical trial. Ertiprotafib is potentially useful for the treatment of Non-Insulin Dependent Diabetes. Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms. Ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta), with an IC(50) of 400nM.
For research use only. We do not sell to patients.